top of page

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

NeuroStar is the First and Only TMS Therapy Cleared
as an Adjunct Treatment For Patients Ages 15 and Older

MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar Advanced Therapy for use as an adjunct for the treatment of major depressive disorder (MDD) in adolescent patients aged 15-21. NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar.

"The prevalence of depression in adolescents and young adults has been accelerating since the COVID-19 pandemic. The current treatment options available for adolescents are extremely limited, compared to those available for adults," according to Dr. Kenneth Pages, Medical Director of TMS of South Tampa. "NeuroStar’s TMS therapy now offers a promising first-line treatment for adolescents, backed by real-world data and impressive response rates consistent with response rates for adults. This advancement has the potential to set a new treatment paradigm for how we address depression in our youth."

The FDA's decision to grant clearance for this new indication is based in part on analyzing real-world data collected through NeuroStar's proprietary TrakStar® platform. This platform provided crucial insights into the treatment's effectiveness and safety profile in adolescents. Among the 1,169 adolescents in the data analysis, 78% achieved clinically meaningful improvement in their depression severity. The FDA reviewed the comprehensive data set from TrakStar, along with clinical data from the published literature, and concluded that NeuroStar TMS was substantially equivalent in terms of safety and effectiveness when used as an adjunct to antidepressant therapy over antidepressant therapy alone in this population.

“Receiving FDA-clearance to treat the adolescent segment aged 15 and up is a treatment solution that is long overdue in the mental health industry,” said Keith J. Sullivan, President and CEO of Neuronetics. “We are excited to offer NeuroStar TMS therapy as a new option for young people and for their concerned parents who have struggled to find a treatment they can be confident in. As a company, we will be focused on driving even more awareness and education about NeuroStar given that this new clearance grows our total addressable market in MDD by 35%.”

NeuroStar is harnessing the versatility of its coil design, enabling providers to address the treatment needs of adolescents with MDD symptoms immediately, all without requiring additional hardware upgrades or purchases. For more information about NeuroStar TMS Therapy, please visit

Serenity Has Been Accepted into NeuroStar TMS’s BMGP


Serenity is thrilled to share that our clinic has been accepted into NeuroStar TMS’s BMGP (Better Me Guarantee Program) as a BMGP Preferred Provider!!!

Neurostar’s network of “Better Me Guarantee Providers” is a group of practices committed to meeting the highest in patient care and quality standards, developed in collaboration with medical experts, attending Neurostar University training, demonstrating prompt response times to patients and advising clients through education about the benefits of a full course of NeuroStar treatment. Serenity is one of two clinics in Minnesota with this recognition!


Be Free to Be Well

Call Today. 952-592-2200

Or Send Us a Message:

bottom of page